Revolutionize your CRC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions and alleviate patient anxiety*! Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy. Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay. 👉 Read more https://lnkd.in/eB8vgaVE Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #MSI #RAS #NRAS #KRAS #BRAF #immunotherapy #ColorectalCancer #CRC *Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.
Biocartis
Medical Equipment Manufacturing
High precision diagnostics for personalized medicine
About us
Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs with a focus in oncology, and expanding its test menu in infectious diseases with partners. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis’ vision is to enable personalized medicine for patients around the world through universal access to molecular testing. Our mission is to make molecular testing actionable, convenient, fast and suitable for any lab. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com
- Website
-
http://www.biocartis.com
External link for Biocartis
- Industry
- Medical Equipment Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Mechelen
- Type
- Privately Held
- Founded
- 2007
- Specialties
- Molecular Diagnostics Solutions, Oncology, and Infectious Diseases
Locations
-
Primary
Generaal de Wittelaan
11B
Mechelen, 2800, BE
-
2 Pierce Palace
Suite 1510
Itasca, Itasca 60143, US
-
Guangzhou, CN
Employees at Biocartis
Updates
-
Smiling faces at the European Meeting on Molecular Diagnostics (EMMD)! Come say hi 👋 🗓 9-11 October 🗺 Noordwijk, Netherlands 📍 Booth 8 Molecular biomarker results in only 3 hours! 💡 THINK IDYLLA Book your meeting 🤝 https://lnkd.in/eedzuQmJ #Biocartis #Idylla #ThinkIdylla #EMMD #EMMD2024 Inès Mademan, Martin Nielsen, Jean-Baptiste Mariaux
-
💡 Let's start innovating together! Biocartis’ mission is to ensure patients and their physicians have access to the right test results at the right time to deliver the right treatment. Interested to partner with us for a companion diagnostic? 👉 Get more information: https://lnkd.in/gyZ9kQZU 👉 Contact our pharma partnering team: https://lnkd.in/dZjHufKA
-
📅 October is Liver Cancer Awareness Month Liver cancer has the 3rd highest mortality rate world wide, with Hepatocellular carcinoma (HCC) being the most common type. Did you know that liver transplantation (LT) is the best curative treatment for HCC patients? 🤔 Unfortunately, it is not always easy to identify which patients should receive LT... 😬 Define the criteria too strictly, you will reject patients that could benefit from LT - define the criteria too loosely, you will overestimate the benefit from a LT for patients who will relapse. ✅ The need for a highly precise and sensitive prognostic tool to identify HCC patients who will benefit from a LT is crucial for improving patient outcomes. Discover Hepatopredict* (CE-IVD) now 👉 https://lnkd.in/euPYNqBW *Developed by Ophiomics, distributed by Biocartis. #LiverCancerAwarenessMonth #LCAM #Biocartis #Ophiomics #HepatoPredict #HCC #HepatocellularCarcinoma #LiverCancer #LT #LiverTransplantation
-
📣 The Belgian Week of Pathology (Brussels, Belgium) is happening NOW! Grab your chance to visit us at booth C28👋 We will be here tomorrow, too 💪 Molecular biomarker results in only 3 hours! 💡 THINK IDYLLA™ Book your meeting now 🤝 https://lnkd.in/evrGrbcr #Biocartis #Idylla #BelgianWeekofPathology #ThinkIdylla #Pathology Marc Millot, Mieke De Buck, Jean-Baptiste Mariaux
-
Why is fast biomarker testing important in LUNG CANCER? 🤔 🧬BIOMARKER TESTING? By analyzing tumor tissue or blood samples, doctors can learn the details of a patient’s specific tumor. If certain biomarkers are identified, cancer therapy can be personalized for each patient which often means more effective therapies. 🏎️ FAST? Patients often receive sub-optimal treatment, rapidly deteriorate or even die while waiting for their biomarker test results(1-3). Patients should be given the most effective treatment first time around, since this not only alleviates patient anxiety(4-5), but also impacts their overall rate of survival(6). 👉 Biomarker results in only 3 hours for fast treatment decisions! THINK IDYLLA™ https://lnkd.in/eKReumqf #Biocartis #Idylla #BiomarkerTesting #PersonalizedMedicine #PrecisionMedicine #LungCancer #NSCLC Sources: https://lnkd.in/ecWyjMnB
-
Revolutionize your NSCLC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions for better patient outcomes! Test for EGFR, ALK, ROS1, RET, METex14 in only 3 hours and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers* 👉 Read more https://lnkd.in/e-qHZv8T Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #GeneFusion #ALK #ROS1 #RET #METex14 #EGFR #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.
-
📣 Join us at the European Meeting on Molecular Diagnostics in Noordwijk, Netherlands from 9 till 11 October! Drop by booth 8 and start your journey with Idylla™. Molecular biomarker results in only 3 hours! ⏱ 🤝 Book your meeting now: https://lnkd.in/eedzuQmJ #EMMD #EMMD2024 #Biocartis #Idylla #ThinkIdylla
-
🎗️October is "Pink Month" or "Breast Cancer Awareness Month", an annual campaign to raise awareness about the impact of breast cancer. Awareness is the first step in the battle against Cancer. Together we rise 🙌❤️ Discover our Breast Cancer Assay Portfolio*: https://lnkd.in/e8is_tei *For Research Use Only (RUO), not for use in diagnostic procedures. #Idylla #Biocartis #APIS #BreastCancerAwarenessMonth #BreastCancer #PIK3CA #AKT1 #ESR1
-
📖 Publication News from the UK Finall et al. (2022) compare NGS to Idylla™ EGFR Mutation Test (CE-IVD*) and illustrate the importance of rapid biomarker testing in NSCLC ❗ 6% of the patients died before the NGS report was available ❗18% of the patients experienced rapid clinical deterioration while waiting for NGS report ❗ 3 patients could have been treated with TKIs while waiting for NGS report ❗ 96.4% agreement between Idylla™ and NGS ❗10% failure rate on NGS ❗ 82% of failed NGS samples rescued by Idylla™ ❗ 5x less tissue used by Idylla™ vs NGS ❗ 19.5 days faster reporting with Idylla™ vs NGS 👉 Rapid EGFR Testing with Idylla™ alongside NGS has the potential to enhance lung cancer patient health outcomes 👈 📚 Read the full publication: https://lnkd.in/eWwgKTr5 👀 Check out the publication summary: https://lnkd.in/eBNGkB4v 🕵️♀️ Discover the Idylla™ EGFR Mutation Test (CE-IVD*): https://lnkd.in/dYX7xNeC *Idylla™ EGFR Mutation Test is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, but is for Research Use Only (RUO), not for use in diagnostic procedures, in the US. #Biocartis #Idylla #LungCancer #NSCLC #EGFR #RapidBiomarkerTesting #BiomarkerTesting #NGS #TKI